Degraders & Molecular Glues – Part 2
Pursuing Challenging Drug Targets, Exploring New Ligases, and Targeting Diverse Indications
4/21/2027 - April 22, 2027 ALL TIMES PDT
From bifunctional degraders such as PROTACs, to monovalent molecular glues, degrader conjugates, and emerging proximity-based modalities, scientists are learning how to redirect the ubiquitin-proteasome, lysosomal, and autophagy machinery to eliminate drug targets once considered “undruggable.” They are exploring new chemistries, broader chemical and target space, novel ligases, and next-generation screening strategies and AI models to understand and predict whether the cellular interactions are selective, efficient, and therapeutically meaningful. This two-part Degraders & Molecular Glues conference brings together leaders across medicinal chemistry, chemical biology, and drug discovery to examine what is working, where the biggest challenges remain, and how targeted degradation and induced proximity are evolving into viable therapeutic strategies.

Wednesday, April 21

Registration Open

Dessert Social in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)

NOVEL DEGRADATION STRATEGIES

Chairperson's Remarks

Milana M. Maletic, PhD, Senior Director, Therapeutic Modalities, Discovery Chemistry, Merck & Co. , Senior Director , Therapeutic Modalities, Discovery Chemistry , Merck & Co.

Novel Strategies for Targeted Degradation of Extracellular and Membrane Proteins

Photo of Weiping Tang, PhD, Professor, Pharmaceutical Sciences and Director, Medicinal Chemistry Center, University of Wisconsin-Madison , Professor , Pharmaceutical Sciences and Director, Medicinal Chemistry Center , University of Wisconsin-Madison
Weiping Tang, PhD, Professor, Pharmaceutical Sciences and Director, Medicinal Chemistry Center, University of Wisconsin-Madison , Professor , Pharmaceutical Sciences and Director, Medicinal Chemistry Center , University of Wisconsin-Madison

Our group is developing novel strategies for the targeted degradation of extracellular and membrane proteins. Recent advances include a degrader with the potential to cross the blood–brain barrier and degrade amyloid aggregates, as well as two distinct catalytic approaches for extracellular protein degradation. These emerging platforms could broaden the therapeutic applications of targeted protein degradation.

Cutting off Proteins at the Source—Sec61 Inhibitors for the Selective Degradation of Target Proteins

Photo of Taoues Temal-Laib, PhD, Associate Director Discovery, Chemistry, Enodia Therapeutics , Associate Director Discovery , Chemistry , Enodia Therapeutics
Taoues Temal-Laib, PhD, Associate Director Discovery, Chemistry, Enodia Therapeutics , Associate Director Discovery , Chemistry , Enodia Therapeutics

The talk will introduce a novel way of removing a protein from a cell i.e. by selectively blocking the translocation of nascent polypeptide chains using selective small molecule inhibitors of the Sec61 translocon.

Coffee & Connection Break in the Exhibit Hall with Poster Viewing

Protein age Bias in Target Degradation by PROTACs

Photo of Xiangshu Xiao, PhD, Professor, Chemical Physiology & Biochemistry, Oregon Health & Science University , Professor , Chemical Physiology & Biochemistry , Oregon Health & Science University
Xiangshu Xiao, PhD, Professor, Chemical Physiology & Biochemistry, Oregon Health & Science University , Professor , Chemical Physiology & Biochemistry , Oregon Health & Science University

Target degradation by PROTACs often exhibits a rebound kinetics where the target protein is initially degraded followed by target rebound, despite the continuous presence of PROTACs. We developed CG-SLENP technology to label new and old proteins in the same cells and we discovered that old proteins are more efficiently degraded while newly synthesized proteins are more resistant to degradation. This discovery adds a new dimension in PROTAC design and evaluation.

Overcoming Clinical Trastuzumab Deruxtecan (T-DXd) Resistance with Next-Generation Degrader-Antibody Conjugates

Photo of Jin Wang, PhD, Director, Biochemistry and Molecular Pharmacology, Baylor College of Medicine , Director , Biochemistry & Molecular Pharmacology , Baylor College of Medicine
Jin Wang, PhD, Director, Biochemistry and Molecular Pharmacology, Baylor College of Medicine , Director , Biochemistry & Molecular Pharmacology , Baylor College of Medicine

Despite the remarkable clinical success of trastuzumab deruxtecan (T-DXd) in HER2-positive and HER2-low cancers, acquired resistance remains a major challenge that limits long-term patient benefit. We have developed a new class of degrader-antibody conjugates (DACs) that combine tumor-selective antibody delivery with targeted protein degradation to eliminate key resistance drivers and enhance anti-tumor activity. This presentation will discuss the design principles, preclinical efficacy, and translational potential of DACs as a next-generation therapeutic modality for overcoming resistance and improving outcomes in refractory breast cancers.

In-Person Breakouts

Presentation to be Announced

In-Person Breakout Discussions (In-Person Only)

In-Person Breakouts are informal, moderated discussions to exchange ideas and develop future collaborations around a focused topic. Please come prepared to be part of a collective, problem-solving session and participate in active idea sharing. Breakout Discussions are offered in-person only.

Close of Day

Dinner Short Course Registration

Thursday, April 22

Morning Coffee

PLENARY KEYNOTE SESSION

PLENARY KEYNOTE SESSION

Plenary Welcome Remarks from Lead Content Director

PLENARY KEYNOTE PRESENTATION: Talk Title to be Announced

Photo of Gwenn Hansen, PhD, CSO, Nurix Therapeutics, Inc. , Chief Scientific Officer , Research , Nurix Therapeutics Inc
Gwenn Hansen, PhD, CSO, Nurix Therapeutics, Inc. , Chief Scientific Officer , Research , Nurix Therapeutics Inc

Coffee & Connection Break in the Exhibit Hall with Poster Viewing and Best Show Awards Announced

TACKLING DIFFICULT ONCOLOGY TARGETS

Chairperson's Remarks

Steven Corsello, MD, Assistant Professor, Department of Medicine, Oncology, Stanford University , Assistant Professor , Department of Medicine- Oncology , Stanford University

Discovery and Optimization of TRIM21 Molecular Glues for Nuclear Pore Complex Degradation

Photo of Steven Corsello, MD, Assistant Professor, Department of Medicine, Oncology, Stanford University , Assistant Professor , Department of Medicine- Oncology , Stanford University
Steven Corsello, MD, Assistant Professor, Department of Medicine, Oncology, Stanford University , Assistant Professor , Department of Medicine- Oncology , Stanford University

Molecular glue mechanisms are notoriously challenging to discover systematically. Through large-scale cell line viability screens, we discovered molecular glues that reprogram the E3 ubiquitin ligase TRIM21 to degrade the nuclear pore complex (NPC). Proteomics and biochemical experiments demonstrated that the molecular glue brings TRIM21 into proximity with NUP98, resulting in NPC destruction and cancer cell apoptosis. Using structural insights, we developed optimized compounds with improved potency and chemical properties.

FEATURED PRESENTATION: Development of Next-Generation Covalent Pan-TEAD Inhibitors

Photo of Anwesha Dey, PhD, Executive Director & Distinguished Scientist, Research Oncology, Genentech Inc. , Executive Director & Distinguished Scientist , Research Oncology , Genentech Inc
Anwesha Dey, PhD, Executive Director & Distinguished Scientist, Research Oncology, Genentech Inc. , Executive Director & Distinguished Scientist , Research Oncology , Genentech Inc

The Path to in vivo KRAS G12D Degradation: Leveraging Integrated Discovery Capabilities

Milana M. Maletic, PhD, Senior Director, Therapeutic Modalities, Discovery Chemistry, Merck & Co. , Senior Director , Therapeutic Modalities, Discovery Chemistry , Merck & Co.

Transition to Lunch

Session Break

VC PANEL

PLENARY PANEL SESSION: INSIGHTS FROM VENTURE CAPITALISTS

Panel Moderator:

PANEL DISCUSSION:
VC Insights on Drug Discovery Trends

Daniel A. Erlanson, PhD, Chief Innovation Officer, Frontier Medicines Corporation , Chief Innovation Officer , Frontier Medicines Corporation

Panelists:

James Edwards, PhD, Venture Partner, Samsara BioCapital , Venture Partner , Samsara BioCapital

Jamie Kasuboski, PhD, Partner, Luma Group , Partner , Luma Group

KT Moortgat, PhD, Managing Partner & Founder, Dalena Capital , Managing Partner & Founder , Dalena Capital

Sonia Setayesh, PhD, Partner, Civilization Ventures , Partner , Civilization Ventures

Chris Smith, PhD, CSO Partner Team, Curie.Bio , VP CSO Partner Team , Drug Discovery , Curie.Bio

Daniella Tedesco, Partner & Co-Founder, NextRound Philanthrophy , Co-Founder , NextRound Philanthrophy

Dessert Social in the Exhibit Hall and Meet the VC Panelists and Poster Awards Announced (Sponsorship Opportunity Available)

TARGET-AGNOSTIC MOLECULAR GLUE DISCOVERY

Chairperson's Remarks

Maria Soloveychik, PhD, Co-Founder & CEO, SyntheX , Co Founder & CEO , SyntheX

Removing Serendipity from Molecular Glue Discovery with ToRNeDO: An Empirical, E3 and Target Agnostic, Cell-Based, Molecular Glue Discovery Platform

Photo of Maria Soloveychik, PhD, Co-Founder & CEO, SyntheX , Co Founder & CEO , SyntheX
Maria Soloveychik, PhD, Co-Founder & CEO, SyntheX , Co Founder & CEO , SyntheX

SyntheX has developed ToRNeDO, a cell-based platform that removes the reliance on serendipity in molecular glue and degrader discovery. It selects glues and degraders directly in living cells using defined target-ligase pairs, mapping novel degrons while bypassing the limits of in vitro assays and in silico methods. Using ToRNeDO, we discovered highly selective glues and degraders against previously untargeted proteins and E3 ligases, making discovery systematic and directed.

Reprogramming VHL: From Target-Agnostic Discovery to New Molecular Glue Substrates

Photo of Jaeki Min, PhD, Senior Principal Scientist, Induced Proximity Platform, Amgen Inc. , Senior Principal Scientist , Induced Proximity Platform , Amgen Inc
Jaeki Min, PhD, Senior Principal Scientist, Induced Proximity Platform, Amgen Inc. , Senior Principal Scientist , Induced Proximity Platform , Amgen Inc

Molecular glue discovery beyond CRBN remains a major challenge. We established a target-agnostic VHL molecular glue discovery platform that integrates VHL-biased libraries with multiomics-based hit discovery, followed by rigorous hit validation and mechanism-of-action characterization using orthogonal cellular and biochemical assays. This approach identified dGEM3 and dCASP2, which recruit distinct structural degrons in GEMIN3 and caspase-2 to VHL, enabling selective ubiquitination and degradation while expanding the addressable VHL substrate landscape.

Chemoproteomic Discovery of Essential, Druggable Proteins in the Wheat Pathogen Z. tritici

Photo of Minjin Yoo, PhD, Postdoctoral Associate, Laboratory of Dr. Benjamin Cravatt, Department of Chemistry, The Scripps Research Institute , Postdoctoral Associate , Chemistry , The Scripps Research Institute
Minjin Yoo, PhD, Postdoctoral Associate, Laboratory of Dr. Benjamin Cravatt, Department of Chemistry, The Scripps Research Institute , Postdoctoral Associate , Chemistry , The Scripps Research Institute

Zymoseptoria (Z.) tritici is a fungal phytopathogen that causes major foliar disease in wheat. We used activity-based protein profiling to generate a covalent ligandability map of Z. tritici, leading to the discovery of electrophilic small molecules that target a diverse set of essential proteins, including covalent ligands that engage an ortholog-restricted cysteine in the GTPase SAR1, leading to its aggregation with other COPII components and impairments in Z. tritici growth.

DEGRADATION STRATEGIES FOR PPI TARGETS

Targeting STAT6 with Inhibitors and VHL-PROTACs for Oral Treatment of Type II Inflammatory Diseases

Photo of Montse Erra, Director Small Molecules Discovery & Development, Molecules R&D, Almirall SA , Dir Small Molecules Discovery & Development , Molecules R&D , Almirall SA
Montse Erra, Director Small Molecules Discovery & Development, Molecules R&D, Almirall SA , Dir Small Molecules Discovery & Development , Molecules R&D , Almirall SA

STAT6 is the transcription factor downstream of IL-4/IL-13 signaling, with IL-13 playing a key role in type II inflammatory diseases. In this talk, we describe the discovery of STAT6 degraders based on proprietary binders and VHL ligands. Further optimization of their physicochemical properties led to orally bioavailable, sub-nanomolar PROTACs. In parallel, a non-SH2 domain DEL-derived hit was optimized to be a potent and safe orally bioavailable clinical candidate.

Increased Therapeutic Index through Cooperative Ternary Complex Formation—The Bcl-xL PROTAC Story

Photo of Andras Kotschy, PhD, Managing Director, Servier Research Institute of Medicinal Chemistry , Managing Dir , Servier Research Institute of Medicinal Chemistry
Andras Kotschy, PhD, Managing Director, Servier Research Institute of Medicinal Chemistry , Managing Dir , Servier Research Institute of Medicinal Chemistry

Bcl-xL is a validated therapeutic target whose systemic inhibition is limited by on-target toxicity. PROTAC-mediated degradation offers a strategy to widen this therapeutic margin by exploiting tissue-selective E3 ligase expression together with cooperative ternary complex formation. These complementary mechanisms restrict efficient Bcl-xL degradation to disease-relevant cells while enhancing degradation potency and selectivity, illustrating how targeted protein degradation can transform the therapeutic index of targets otherwise constrained by systemic pharmacological inhibition.

Discovery of a Potent and Selective Molecular Glue Degrader of PPIL4 Active in Pediatric Acute Leukemia and Medulloblastoma Models

Photo of Gisele Nishiguchi, PhD, Group Leader, St. Jude Children's Research Hospital , Group Leader , St. Jude Children's Research Hospital
Gisele Nishiguchi, PhD, Group Leader, St. Jude Children's Research Hospital , Group Leader , St. Jude Children's Research Hospital

Phenotypic screening of St. Jude’s proprietary CRBN-based molecular glue library against pediatric cancer cell lines identified a potent cytotoxic compound. Mechanistic and proteomics profiling identified PPIL4 as a novel neosubstrate, confirmed by cryo-EM structure of ternary complex. In vivo studies showed reduced tumor burden and increased survival in B-ALL and medulloblastoma mouse models.

Close of Conference


For more details on the conference, please contact:
Tanuja Koppal, PhD
Senior Conference Director
Cambridge Healthtech Institute
Email: [email protected]

For sponsorship information, please contact:
Kristin Skahan
Senior Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5431
Email: [email protected]


Register Early for Maximum Savings

APRIL 19

Covalent & Induced Proximity-Based Therapies

RNA-Modulating Small Molecule Drugs

Generative AI for Drug Discovery

training seminars

View In-Person Short Courses

APRIL 20 - 21

Degraders & Molecular Glues - Part 1

Small Molecule Discovery Technologies

AI/ML for Early Drug Discovery - Part 1

Linker & Conjugation Chemistries

Peptides

APRIL 21 - 22

Degraders & Molecular Glues - Part 2

Protein-Protein Interactions / Difficult Targets

AI/ML for Early Drug Discovery - Part 2

DNA-Encoded Libraries

GLP1 & Oral Peptides


Drug Discovery Chemsitry Europe

View All Sponsors

View All Media Partners